Since HSP and immune checkpoint expression are associated with T cell activation, we next sought to analyze the effect of HSP90 inhibitors alone or in combination with PD-1 or CTLA-4 inhibitors on T cell degranulation response in lymphoma patients. Here, HSP90AA1 is linked to lymphoma.